CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...

LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of ...

Variants of the KCNC1 gene impact K v 3.1 potassium channel function, resulting in neurodevelopmental disorders which can include progressive myoclonic epilepsy (PME) and developmental epileptic ...

Autifony Therapeutics Ltd. has described compounds acting as modulators of voltage-gated potassium channels from the Kv3 subfamily, such as Kv3.1, Kv3.2 and/or Kv3.3, reported to be useful for the ...

LOWELL, Mass.--(BUSINESS WIRE)--MACOM Technology Solutions Inc. (“MACOM”) today announced the availability of its new dual channel 96 GBaud transimpedance amplifier (TIA) and quad-channel modulator ...

Bsense Bio Therapeutics Ltd. has nominated BSEN-760, a dual Kv7.2/3 and TRPV1 ion channel modulator, as a clinical candidate for the treatment of chronic pain.

Please provide your email address to receive an email when new articles are posted on . The Osprey and Apteryx trials will assess QLS-111, a potassium channel modulator, in patients with glaucoma. The ...

(MENAFN- EIN Presswire) EINPresswire/ -- The global ion channel modulators market is entering a decade of sophisticated molecular innovation, with its valuation projected to rise from USD 13.3 billion ...